Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer-Reference-Cited by-同舟云学术

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Published:2019-08-07 Issue:504 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

McDonald Bradon R.¹^ORCID,Contente-Cuomo Tania¹,Sammut Stephen-John²^ORCID,Odenheimer-Bergman Ahuva¹,Ernst Brenda³^ORCID,Perdigones Nieves¹^ORCID,Chin Suet-Feung²^ORCID,Farooq Maria¹^ORCID,Mejia Rosa⁴,Cronin Patricia A.³,Anderson Karen S.³⁵,Kosiorek Heidi E.³,Northfelt Donald W.³,McCullough Ann E.³^ORCID,Patel Bhavika K.³^ORCID,Weitzel Jeffrey N.⁴^ORCID,Slavin Thomas P.⁴,Caldas Carlos²^ORCID,Pockaj Barbara A.³^ORCID,Murtaza Muhammed¹³^ORCID

Affiliation:

1. Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.

2. Department of Oncology and Cancer Research UK Cambridge Institute and Cancer Centre, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.

3. Mayo Clinic, Scottsdale, AZ 85259, USA.

4. City of Hope, Duarte, CA 91010, USA.

5. Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.

Abstract

A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.

Funder

National Institutes of Health

V Foundation for Cancer Research

Science Foundation Arizona

Ben and Catherine Ivy Foundation

Cancer Research UK

Publisher